Current Report Filing (8-k)
29 May 2014 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 22, 2014
FURIEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
|
|
| 001-34641 |
|
27-1197863 |
| (Commission
File Number) |
|
(IRS Employer
ID Number) |
|
|
|
| 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code (919) 456-7800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2014 annual meeting of stockholders for Furiex Pharmaceuticals, Inc. was held on May 22, 2014.
At the meeting, our stockholders elected six members to our board of directors for a term expiring at the annual meeting of stockholders in
2015, as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
| Members |
|
Number of Shares
Voted For |
|
|
Number of Shares
Against or Withheld
(Includes Abstentions) |
|
|
Broker Non-Votes |
|
| June S. Almenoff, M.D., Ph.D. |
|
|
7,063,805 |
|
|
|
176,447 |
|
|
|
2,205,332 |
|
| Peter B. Corr, Ph.D. |
|
|
7,190,536 |
|
|
|
49,716 |
|
|
|
2,205,332 |
|
| Stephen R. Davis |
|
|
7,156,440 |
|
|
|
83,812 |
|
|
|
2,205,332 |
|
| Wendy L. Dixon, Ph.D. |
|
|
6,784,738 |
|
|
|
455,514 |
|
|
|
2,205,332 |
|
| Fredric N. Eshelman, Pharm.D. |
|
|
6,982,510 |
|
|
|
257,742 |
|
|
|
2,205,332 |
|
| Stephen W. Kaldor, Ph.D. |
|
|
7,156,442 |
|
|
|
83,810 |
|
|
|
2,205,332 |
|
Our stockholders also ratified the appointment of Deloitte & Touche LLP as our independent registered
public accounting firm for the fiscal year ending December 31, 2014. The vote for such ratification was 9,274,872 shares for and 170,712 shares against (including abstentions).
At the meeting, our stockholders approved the advisory resolution approving the compensation of our named executive officers as presented in
the Company’s proxy statement related to the annual meeting. The vote for such proposal was 7,110,618 shares for, 129,634 shares against (including abstentions) and 2,205,332 broker non-votes.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
FURIEX PHARMACEUTICALS, INC. |
|
|
|
| Date: May 28, 2014 |
|
|
|
|
|
|
|
|
/s/ Sailash I. Patel |
|
|
|
|
Sailash I. Patel |
|
|
|
|
Chief Financial Officer |
(MM) (NASDAQ:FURX)
Historical Stock Chart
From Oct 2024 to Nov 2024
(MM) (NASDAQ:FURX)
Historical Stock Chart
From Nov 2023 to Nov 2024
